Oxidative stress, anti-oxidants and the cross-sectional and longitudinal association with depressive symptoms: results from the CARDIA study

CN Black1, BWJH Penninx1, M Bot1, AO Odegaard2, MD Gross3, KA Matthews4 and DR Jacobs Jr5

Depression may be accompanied by increased oxidative stress and decreased circulating anti-oxidants. This study examines the association between depressive symptoms, F2-isoprostanes and carotenoids in a US community sample. The study includes 3009 participants (mean age 40.3, 54.2% female) from CARDIA (Coronary Artery Risk Development in Young Adults). Cross-sectional analyses were performed on data from the year 15 examination (2000–2001) including subjects whose depressive symptoms were assessed with the Center for Epidemiologic Studies Depression Scale (CES-D) and had measurements of plasma F2-isoprostanes (gas chromatography/mass spectrometry) or serum carotenoids (high-performance liquid chromatography). Carotenoids zeaxanthin/lutein, α-carotene, β-carotene were standardized and summed. Longitudinal analyses were conducted using the data from other examinations at 5-year intervals. Cross-lagged analyses investigated whether CES-D predicted F2-isoprostanes or carotenoids at the following exam, and vice versa. Regression analyses were controlled for sociodemographics, health and lifestyle factors. F2-isoprostanes were higher in subjects with depressive symptoms (CES-D ≥ 16) after adjustment for sociodemographics (55.7 vs 52.0 pg ml−1; Cohen’s d = 0.14, P < 0.001). There was no difference in F2-isoprostanes after further adjustment for health and lifestyle factors. Carotenoids were lower in those with CES-D scores ≥ 16, even after adjustment for health and lifestyle factors (standardized sum 238.7 vs 244.0, Cohen’s d = −0.16, P < 0.001). Longitudinal analyses confirmed that depression predicts subsequent F2-isoprostane and carotenoid levels. Neither F2-isoprostanes nor carotenoids predicted subsequent depression. In conclusion, depressive symptoms were cross-sectionally and longitudinally associated with increased F2-isoprostanes and decreased carotenoids. The association with F2-isoprostanes can largely be explained by lifestyle factors, but lower carotenoids were independently associated with depressive symptoms.

Translational Psychiatry (2016) 6, e743; doi:10.1038/tp.2016.5; published online 23 February 2016

INTRODUCTION

Depression, besides being a leading cause of poor functioning and disability,1 is an independent predictor of the onset of somatic disease.2 Relative to individuals without, individuals with depression have a higher risk of developing cardiovascular disease,3 obesity,4 diabetes,6 cancer7 and cognitive impairment8 and have increased mortality rates.8 These associations have been found not only in individuals with major depressive disorder, but also in those with depressive symptoms.2 Increased oxidative stress and decreased antioxidant levels may be key mechanisms in this association. Oxidative stress is a complex and dynamic biological process that refers to the damaging effects of reactive oxygen species (ROS). ROS are normal products of aerobic metabolism and the body has a range of antioxidant defenses to protect against their potentially harmful effects. However, when there is either an increase in exposure to (or production of) ROS, or a decrease in anti-oxidants levels, damage may occur to lipids, proteins and DNA resulting in cellular dysfunction and disease, or ultimately cell death.9

A recent meta-analysis10 demonstrated that oxidative stress levels measured by F2-isoprostanes (reflecting oxidative lipid damage) are increased in persons with major depression and/or depressive symptoms, but the number of studies and their sample sizes were limited and many studies did not account for important potential confounding factors. Oxidative stress is associated with a range of sociodemographic, health and lifestyle factors, for example, socioeconomic status and smoking,9,11,12 that are also known to be associated with depression.5,13–15 If taken into account, these factors could considerably influence the estimate of the association.

There is also evidence suggesting that anti-oxidants are decreased in depression, illustrated by lower antioxidant levels,16 including carotenoids,17,18 and antioxidant enzymes in persons with depressive symptomatology.19 Measuring oxidative stress in vivo is challenging; levels of ROS are not easily determined owing to their short half-life and highly reactive nature. Alternative approaches include measurements of oxidative damage to protein, lipids or DNA or of levels of antioxidants.

F2-isoprostanes are currently considered to be the marker of choice for oxidative lipid damage.20–23 F2-isoprostanes are formed...
Carotenoids have antioxidant capacity. This property may contribute to observational studies finding higher carotenoid levels to be associated with reduced risks of metabolic syndrome, diabetes mellitus, cardiovascular disease, and cancer. In humans, the most important carotenoids include β-carotene, lycopene, zeaxanthin/lutein and β-cryptoxanthin. They owe their potent antioxidant action to their ability to quench ROS. As highly lipophilic molecules, they are located in the lipid bilayer of the cell membrane where they protect against lipid peroxidation. Studying carotenoids in unison with the F2-isoprostanes provides insight into two important and interdependent aspects of redox homeostasis.

This study describes the cross-sectional associations of depressive symptoms with F2-isoprostanes and carotenoids in large community samples, taking into account a wide range of important sociodemographic, health and lifestyle factors. In particular, this study includes data on dietary patterns, which is not available for the majority of previous research. Dietary patterns may be an important potential confounding factor in the association with depression; dietary intake is the sole source of carotenoids in humans and F2-isoprostanes have previously been demonstrated to be associated with dietary pattern independently of other health and lifestyle factors. In addition, this study examines the relationships between F2-isoprostanes, carotenoids and depressive symptoms over multiple time points to gain insight into the temporal directionality of the association as it is unclear whether oxidative stress leads to depressive symptoms or vice versa. It is possible that depressive symptoms lead to unhealthy behaviors that in turn increase exposure to oxidative stress. Alternatively, increased oxidative stress, to which the brain is particularly vulnerable, may cause oxidative damage, making an individual susceptible to developing depressive symptoms.

This report comprises, to our knowledge, the largest sample in a study of oxidative stress and anti-oxidants with depression. The cross-sectional analyses in this study were conducted with data from the year 15 CARDIA assessment, as this is the only time point that allowed analysis of both F2-isoprostanes and carotenoids (see Figure 1) with depressive symptoms. The sample comprised 3009 participants for whom data were available on depressive symptoms measured by the Center for Epidemiologic Studies Depression Scale (CES-D) and data on either F2-isoprostanes (n = 2974) or carotenoids (n = 2889). For the longitudinal analyses, data were used on F2-isoprostanes from years 15 and 20, and carotenoids from baseline and years 7 and 15, and CES-D from years 5, 10, 15 and 20.

Depressive symptoms
Depressive symptoms were assessed using the 20-item CES-D. Subjects indicate on a four-point scale how often they experienced a symptom in the past week. Four items relating to positive affect are reverse scored and the overall score is a sum of the responses across the 20 items (possible range 0–60). A cutoff score of ≥16 indicates a clinically significant depressed mood. The CES-D has been found to have good internal consistency and adequate test–retest reliability. Construct validity of the scale is supported by correlations with other self-report measures, clinical ratings of depression, and clinical interviews.

CES-D scores were analyzed in four different ways. First, total CES-D scores were analyzed as a continuous measure. Second, the CES-D was used as a categorical measure using the cutoff score ≥16. Third, a categorical measure based on CES-D scores and antidepressant use comparing subjects with CES-D ≥16 and/or current antidepressant to subjects with CES-D < 16 and no antidepressant use was created. (Data on antidepressant use was obtained through a structured interview assessed at the same examination point.) Finally, to study the impact of exposure to chronic depressive symptoms, a count variable was created representing the number of times the CES-D was ≥16 based on the assessments at years 5, 10 and 15. Subjects were compared with those who never had a CES-D score ≥16.

Oxidative stress and anti-oxidants
All the participants were instructed to adhere to an overnight fast and were asked to avoid smoking and heavy physical activity for at least 2 h before blood collection at each examination. After serum and plasma separation from whole blood, aliquots were stored at −70 °C until they were shipped on dry ice to a central laboratory.

Plasma F2-isoprostanes.
YALTA used plasma obtained at CARDIA years 15 and 20 to measure F2-isoprostanes with a gas chromatography–mass spectrometry-based method by the Molecular Epidemiology and Biomarker Research Laboratory at the University of Minnesota (Minneapolis, MN, USA), as previously described. All the samples were analyzed within 1 year of collection. Substudies demonstrated stability of F2-isoprostanes (no ex vivo loss or formation) during blood collection and processing procedures. Analytical variation of the method was 10% for each of three control pools assembled in 2000 and assayed repeatedly between October 2000 and August 2007; the values of these control pools were stable over time, implying that both assay and stored samples were stable. Thus, year 15 and 20 plasma F2-isoprostane concentrations are directly comparable.

Serum carotenoids.
YALTA used sera obtained at CARDIA years 0, 7 and 15 to assay carotenoids, α- and β-carotene, lycopene, zeaxanthin/lutein and β-cryptoxanthin (Molecular Epidemiology and Biomarker Research Laboratory, University of Minnesota), with an HPLC-based assay modified from the method of Bieri et al. to optimize detection of carotenoids with calibration as described by Craft et al. and sample handling as described
by Gross et al.\textsuperscript{13} Calibration was performed with pure compounds (Hoffmann-La Roche, Basel, Switzerland; Sigma Chemical (now Sigma-Aldrich, St Louis, MO, USA)). Quality-control procedures included routine analysis of plasma and serum control pools containing high and low concentrations of each analyte. In addition, the laboratory routinely analyzed NIST reference sera and was a participant in the NIST Fat-Soluble Vitamin Quality Assurance Group. The coefficients of variance were <10% for all analytes and control pools. The intra-class correlation coefficients (between-person variance/between-person plus within-person variance) were 0.93 for \(\alpha\)-carotene, 0.98 for \(\beta\)-carotene, 0.73 for zeaxanthin/lutein, 0.97 for \(\beta\)-cryptoxanthin and 0.73 for lycopene.\textsuperscript{44}

From a dietary and physiological perspective, the five carotenoids (zeaxanthin/lutein, \(\beta\)-cryptoxanthin, lycopene, \(\alpha\)- and \(\beta\)-carotene) are closely intercorrelated and were therefore analyzed as a total carotenoid (sum of five carotenoids) and as well as individually, similar to previous reports on carotenoids in this sample\textsuperscript{45} and previous studies on carotenoids and depressive symptoms.\textsuperscript{36}

Covariates

Demographic variables. Participants' age, sex and race were assessed by self-report. Education was assessed by asking participants to report their highest level of education.

Number of somatic diseases. Participants reported whether they had ever been diagnosed with any of twenty-seven major or chronic health conditions, and whether they had had these conditions in the past year (see footnote ‘d’ in Table 1). The total number of self-reported diagnoses of diseases served as the covariate.

Supplement use. Participants were asked whether they had used any vitamin or mineral supplements in the past year as part of the CARDIA Diet Practices, Behaviors and Attitudes Questionnaire. Those using a multi-vitamin, vitamin A, C, E, beta-carotene or an antioxidant combination were defined as supplement users.

Diet quality. Diet was assessed at years 0, 7 and 20 through an interviewer-administered validated diet history in which participants were asked open-ended questions about their dietary pattern in the last month. Food groups were classified as beneficial (\(n = 20\)), adverse (\(n = 13\)) or neutral (\(n = 13\)) in terms of hypothesized health effects. This score (A Priori Diet Quality Score) has been previously described in more detail.\textsuperscript{36} The theoretical range of score is 0–132 with higher scores indicating higher hypothesized diet quality. This diet quality score is characterized by long-term stability. Correlation coefficients for dietary scores at years 0 and 7, and years 7 and 20 were 0.65 and 0.64, respectively. As dietary data are not available for the year 15 assessment, the mean of the year 0, 7 and 20 diet scores was calculated based on as many of the three data points as were available.

Smoking status. Self-reported smoking was classified as nonsmoker (never and former) or current smoker.

Alcohol consumption. Participants were categorized as non-drinker, moderate drinker (\(\leq 14\) units per week for males and \(\leq 7\) units per week for females) or heavy drinker (\(> 14\) units per week for males and \(> 7\) units per week for females).

Physical activity. A validated interview-administered questionnaire (CAR-\(D\)IARY Physical Activity History, a simplified version of the Minnesota Leisure Time Physical Activity Questionnaire\textsuperscript{46}) was used to assess physical activity in the past year, from which exercise units were calculated.

Body mass index. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m\(^2\)). Height and weight were recorded to the nearest 0.5 cm and 0.2 kg.

All scales used to assess health behaviors are accessible on http://www.cardia.domp.uab.edu/.

Statistical analyses

Statistical analyses were performed using SPSS version 20.0 (IBM, Armonk, NY, USA). Independent \(t\)-tests were used to compare means of continuous variables and chi-square tests to compare categorical variables between persons with and without depressive symptoms. To analyze total carotenoids, a sum score of the standardized values (\(t\)-scores) of the five carotenoids was created. F2-isoprostanes and the sum of five carotenoids were log-transformed for the analysis.

Linear regression examining the cross-sectional association between F2-isoprostanes or carotenoids (dependent variables) and CES-D scores (main predictor) were conducted with three models. Model 1 was adjusted for sociodemographics (age, sex, race and education); model 2 was additionally adjusted for supplement use and the number of somatic diseases; model 3 was additionally adjusted for health and lifestyle factors, including diet, BMI, smoking, alcohol consumption and physical activity. All the models were adjusted for research center (Birmingham, AL; Chicago, IL; Minneapolis, MN or Oakland, CA). Analysis of covariance was used to calculate the mean levels of F2-isoprostanes and carotenoids in those with and without depressive symptoms (CES-D cutoff \(\geq 16\)). Reported levels were back-transformed to geometric means. Effect’s sizes Cohen’s \(d\) were calculated on the basis of the means, standard deviations and number of subjects.

To demonstrate which health and lifestyle factors had the greatest effects on the association between F2-isoprostanes/carotenoids and CES-D scores, change of estimate analyses were conducted. Models were created for each health and lifestyle factor by adding them to the model already adjusted for sociodemographics (model 1). The percentage of change in standardized regression coefficient of the CES-D score after the addition of a health and lifestyle factor was calculated for each covariate.

To determine whether depressive symptoms predict oxidative stress levels over time (or vice versa), cross-lagged linear regression analyses were conducted. F2-isoprostane levels at year 20 (dependent variable) and CES-D at year 15 (main predictor) were adjusted for covariates at year 15 and F2-isoprostanes at year 15. Similarly, analyses were conducted with CES-D at year 20 (dependent variable) and F2-isoprostanes at year 15 (main predictor), adjusted for covariates at year 15 and CES-D at year 15. For the sum of the five carotenoids at year 15, cross-lagged analyses were conducted with CES-D at year 10 as the main predictor, with covariates at year 10, additionally adjusted for carotenoids at year 7 (no data were available for carotenoids at year 10). Finally, analyses were conducted with CES-D at year 20 (dependent variable) and the carotenoids at year 15 (main predictor), adjusted for covariates at year 15 and CES-D at year 15.

RESULTS

Sample characteristics

The sample was 54% female, 55% white and the mean age was 40.3 years (s.d. 3.6). The mean CES-D score was 8.9 (s.d. 7.7) with 15.7% scoring \(\geq 16\) and 20.0% scoring \(\geq 16\) and/or currently using antidepressants. Those with a CES-D score \(\geq 16\) were more likely to be female, black and have less than high school education. They differed significantly from those with CES-D score lower than 16 on all health and lifestyle factors, except supplement use. Those with depressive symptoms were more likely to be smokers, heavy drinkers, have a higher BMI, have somatic diseases; model 3 was additionally adjusted for health and lifestyle factors, including diet, BMI, smoking, alcohol consumption and physical activity. All the models were adjusted for research center (Birmingham, AL; Chicago, IL; Minneapolis, MN or Oakland, CA). Analysis of covariance was used to calculate the mean levels of F2-isoprostanes and carotenoids in those with and without depressive symptoms (CES-D cutoff \(\geq 16\)). Reported levels were back-transformed to geometric means. Effect’s sizes Cohen’s \(d\) were calculated on the basis of the means, standard deviations and number of subjects.

To determine whether depressive symptoms predict oxidative stress levels over time (or vice versa), cross-lagged linear regression analyses were conducted. F2-isoprostane levels at year 20 (dependent variable) and CES-D at year 15 (main predictor) were adjusted for covariates at year 15 and F2-isoprostanes at year 15. Similarly, analyses were conducted with CES-D at year 20 (dependent variable) and F2-isoprostanes at year 15 (main predictor), adjusted for covariates at year 15 and CES-D at year 15. For the sum of the five carotenoids at year 15, cross-lagged analyses were conducted with CES-D at year 10 as the main predictor, with covariates at year 10, additionally adjusted for carotenoids at year 7 (no data were available for carotenoids at year 10). Finally, analyses were conducted with CES-D at year 20 (dependent variable) and the carotenoids at year 15 (main predictor), adjusted for covariates at year 15 and CES-D at year 15.

F2-isoprostanes

Cross-sectional analyses. CES-D (continuous score) was positively associated with F2-isoprostanes after adjustment for sociodemographics (model 1: \(\beta = 0.05, P = 0.009\)) and supplement use and somatic disease (model 2: \(\beta = 0.05, P = 0.010\); Table 3). After additional adjustment for lifestyle, there was no association between CES-D and F2-isoprostanes (model 3: \(\beta = 0.01, P = 0.731\)). In depressed subjects (CES-D \(\geq 16\)), the mean F2-isoprostane level was 55.7 pg ml\(^{-1}\) (95% CI = 53.6–58.0) vs 52.0 pg ml\(^{-1}\) (95% CI = 51.0–53.1) in the non-depressed after adjustment for sociodemographics (model 1: Cohen’s \(d = 0.14, P = 0.001; \text{Figure 2}\)). There was no significant difference between the groups after adjustment for health and lifestyle factors: mean
F2-isoprostane level was 57.5 pg ml⁻¹ (95% CI = 55.4–59.9) in depressed versus 55.7 pg ml⁻¹ in non-depressed subjects (95% CI = 54.4–57.0; P = 0.113; Figure 2a). Change in estimate analyses revealed BMI, smoking and diet had the greatest effects on the association (See Supplementary Table 3).

Depression defined as CES-D ≥ 16 and/or current antidepressant use was positively associated with F2-isoprostanes after adjustment for sociodemographics (model 1: β = 0.06, P < 0.001) and after health and lifestyle (model 3: β = 0.03, P = 0.047). The association of F2-isoprostanes and the number of times that CES-D scores were ≥ 16 over the years 5, 10 and 15 was significant for those with increased scores two or three times (after adjustment for sociodemographics), illustrating the association was stronger when depressive symptoms had a more chronic course (model 1: CES-D ≥ 16 two times, β = 0.05, P = 0.009; CES-D ≥ 16 three times, β = 0.04, P = 0.033). The association was no longer significant after additional adjustment for health and lifestyle (model 3: CES-D ≥ 16 two times, β = 0.03, P = 0.111; CES-D ≥ 16 three times, β = 0.01, P = 0.603).

Cross-lagged longitudinal analyses. Cross-lagged analyses of CES-D and F2-isoprostanes at years 15 and 20 revealed CES-D ≥ 16 (as well as CES-D ≥ 16 and/or current antidepressant) at year 15 were associated with higher F2-isoprostanes at year 20 (model 1: β = 0.05, P = 0.003; Table 4). These findings remained significant after adjustment for health and lifestyle factors (model 3: β = 0.03,

---

**Table 1. Sample characteristics by depressive symptoms (CES-D < 16 or ≥ 16)**

| CARDIA exam year 15 | CES-D < 16 | CES-D ≥ 16 | P | Total |
|---------------------|------------|------------|---|-------|
| (N = 2538)          |            |            |   | (N = 3009) |
| **Oxidative stress** |            |            |   |       |
| F2-isoprostanes pg ml⁻¹ | Median (IQR) | 58.2 (38.2–68.3) | 55.4 (41.9–75.0) | < 0.001 | 50.9 (38.5–69.4) |
| **Carotenoids** |            |            |   |       |
| Sum of five carotenoids (t-scores)b | Median (IQR) | 252.0 (228.6–268.5) | 234.4 (221.3–252.4) | < 0.001 | 243.4 (227.2–266.50) |
| Zeaxanthin/lutein μg dl⁻¹ | Median (IQR) | 25.9 (17.5–31.3) | 20.2 (15.6–27.6) | < 0.001 | 23.1 (17.1–30.7) |
| β-cryptoxanthin μg dl⁻¹ | Median (IQR) | 12.1 (6.5–15.2) | 8.4 (5.8–12.9) | < 0.001 | 9.6 (6.4–14.7) |
| Lycopene μg dl⁻¹ | Median (IQR) | 40.2 (27.3–50.4) | 35.0 (24.4–46.0) | < 0.001 | 37.7 (26.9–49.7) |
| α-carotene μg dl⁻¹ | Median (IQR) | 5.9 (2.0–7.3) | 2.6 (1.3–1.4) | < 0.001 | 3.7 (1.9–6.9) |
| β-carotene μg dl⁻¹ | Median (IQR) | 22.5 (9.5–16.4) | 12.1 (7.1–20.1) | < 0.001 | 15.6 (9.1–26.4) |
| **Depressive symptoms** |            |            |   |       |
| CES-D Mean (s.d.) | 6.3 (4.2) | 22.8 (7.0) | 8.9 (7.7) |       |       |
| CES-D ≥ 16 | — | — | — |       |       |
| CES-D ≥ 16 and/or antidepressant use | — | — | — |       |       |
| Antidepressant users | 5.1% | 19.1% | < 0.001 | 7.3% |       |
| N of times CES-D ≥ 16 over years 0, 10 and 15 | 75.4% | — | < 0.001 | 63.9% |       |
| of times CES-D ≥ 16 | 0 | 75.4% | — | < 0.001 | 63.9% |
| 1 | 19.3% | 29.0% | < 0.001 | 20.8% |       |
| 2 | 5.3% | 35.0% | 9.8% |       |       |
| 3 | — | 36.0% | 5.5% |       |       |
| **Sociodemographics** |            |            |   |       |
| Age Mean (s.d.) | 40.3 (3.6) | 40.1 (3.7) | 0.15 | 40.3 (3.6) |       |
| Female | 52.4% | 63.9% | < 0.001 | 54.2% |       |
| White | 58.3% | 37.2% | < 0.001 | 55.0% |       |
| Education | — | — | < 0.001 |       |       |
| ≤ High school | 44.4% | 55.9% | 46.2% |       |       |
| (some) College | 43.6% | 33.3% | 42.0% |       |       |
| ≥ Master’s degree | 11.9% | 10.9% | 11.8% |       |       |
| **Health and lifestyle** |            |            |   |       |
| N somatic diseases & | Mean (s.d.) | 0.9 (1.1) | 1.4 (1.5) | < 0.001 | 1.0 (1.2) |
| Supplement users & | 61.4% | 62.2% | 0.74 | 61.5% |       |
| Diet quality score & | Mean (s.d.) | 67 (11) | 63 (11) | < 0.001 | 67 (11) |
| Smoking | Non (never and former) | 81.8% | 65.7% | < 0.001 | 79.3% |
| Current | 18.2% | 34.3% | 20.7% |       |       |
| Alcohol | — | — | < 0.001 |       |       |
| % of 0 units per week | 46.5% | 50.1% | 47.1% |       |       |
| % of 14/9 ≤ 7 units per week | 42.0% | 33.3% | 40.7% |       |       |
| % of > 14/9 > 7 units per week | 11.5% | 16.6% | 12.3% |       |       |
| BMI kg/m² | Mean (s.d.) | 28.3 (6.0) | 29.7 (7.3) | < 0.001 | 28.5 (6.2) |
| Physical activity (exercise units) | Mean (s.d.) | 367 (290) | 281 (252) | < 0.001 | 353 (286) |

Abbreviations: BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults; CES-D, Center for Epidemiologic Studies Depression Scale; IQR, interquartile range; N, number. *Year 15 N = 3009 with valid CES-D score and valid F2-isoprostane (N = 2974), at least one carotenoid value (N = 2889), all five carotenoid values (N = 2865). ∼Sum of standardized values (t-scores) of zeaxanthin/lutein, β-cryptoxanthin, lycopene, α-carotene, β-carotene. ∗Number of times CES-D ≥ 16 over assessments at CARDIA exam years 5, 10, 15. ∗∗Number of somatic diseases included in count: high blood pressure, high cholesterol, heart problem, diabetes, hepatitis in the past year, kidney failure/dialysis/transplant in the past year, nephritis in the past year, other kidney disease in the past year, liver cirrhosis, other liver disease in the past year, gallstones in the past year, migraine in the past year, peripheral vascular disease, cancer (ever), thyroid disease (ever), ulcer in the past year, other digestive disease in the past year, gout in the past year, asthma in the past year, epilepsy with seizures in the past year, tuberculosis in the past year, emphysema in the past year, multiple sclerosis in the past year, stroke in the past year, chronic bronchitis in the past year, HIV (ever), blood clot (past year), other major disease, polycystic ovarian syndrome. ∗∗Use of a multivitamin, vitamin A, C, E, beta-carotene or an antioxidant combination. ∗Average score over CARDIA exam years 0, 7 and 20.
Table 2. Cross-sectional univariate associations of F2-isoprostanes and carotenoids with covariatesa

| CARDIA exam year 15 | F2-isoprostanes | Sum of five carotenoidsb |
|---------------------|----------------|-------------------------|
|                     | β              | P           | β              | P           |

**Depressive symptoms**
- CES-D
- CES-D ≥ 16
- CES-D ≥ 16 and/or antidepressant use

**Antidepressant users**
- N of times CES-D ≥ 16
- over years 0, 10 and 15

**Sociodemographics**
- Age
- Sex (male reference)
- Race (white reference)
- Education

**Health and lifestyle**
- N somatic diseasesd
- Supplement usersf
- Diet quality scoreg
- Smoker (non (never and former)
- Alcohol
- BMI kg/m²
- Physical activity

Abbreviations: BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults; CES-D, Center for Epidemiologic Studies Depression Scale; N, number; Ref., reference. aF2-isoprostanes and carotenoids log-transformed for linear regression analysis. Results are reported as standardized regression coefficients. All the results are adjusted for CENTER at baseline. bSum of standardized values (z-scores) of zeaxanthin/lutein, ß-cryptoxanthin, lycopene, α-carotene, ß-carotene cComparison of 1, 2 or 3 times CES-D ≥ 16 with CES-D score 0 times ≥ 16 (over CARDIA exam years 5, 10, 15) dNumber of self-reported somatic diseases included in count: high blood pressure, high cholesterol, heart problem; diabetes, hepatitis in the past year, kidney failure/dialysis/ transplant in the past year, nephritis in the past year, other kidney disease in the past year, liver cirrhosis, other liver disease in the past year, gallstones in the past year, migraine in the past year, peripheral vascular disease, cancer (ever), thyroid disease (ever), ulcer in the past year, other digestive disease in the past year, gout in the past year, asthma in the past year, epilepsy with seizures in the past year, tuberculosis in the past year, emphysema in the past year, multiple sclerosis in the past year, stroke in the past year, chronic bronchitis in the past year, HIV (ever), blood clot (past year), other major disease, polycystic ovarian syndrome. eUse of a multivitamin, vitamin A, C, E, beta-carotene or an antioxidant combination. fAverage score over CARDIA exam years 0, 7 and 20. gAverage score over years 0, 10 and 15. hSum of standardized values (z-scores) of zeaxanthin/lutein, ß-cryptoxanthin, lycopene, α-carotene, ß-carotene. iComparison of 1, 2 or 3 times CES-D ≥ 16 with CES-D score 0 times ≥ 16 (over CARDIA exam years 5, 10, 15) jNumber of self-reported somatic diseases included in count: high blood pressure, high cholesterol, heart problem; diabetes, hepatitis in the past year, kidney failure/dialysis/ transplant in the past year, nephritis in the past year, other kidney disease in the past year, liver cirrhosis, other liver disease in the past year, gallstones in the past year, migraine in the past year, peripheral vascular disease, cancer (ever), thyroid disease (ever), ulcer in the past year, other digestive disease in the past year, gout in the past year, asthma in the past year, epilepsy with seizures in the past year, tuberculosis in the past year, emphysema in the past year, multiple sclerosis in the past year, stroke in the past year, chronic bronchitis in the past year, HIV (ever), blood clot (past year), other major disease, polycystic ovarian syndrome. kUse of a multivitamin, vitamin A, C, E, beta-carotene or an antioxidant combination. lAverage score over CARDIA exam years 0, 7 and 20.

F2-isoprostanes at year 15 were associated with CES-D scores at year 20 after adjustment for sociodemographics (model 1: β = 0.04, P = 0.028), but not after further adjustment for health and lifestyle (model 3: β = 0.03, P = 0.095).

Carotenoids

Cross-sectional analyses. CES-D (continuous score) was negatively associated with the sum of five carotenoids after adjustment for sociodemographics (model 1: β = −0.13, P < 0.001), and after additional adjustment for supplement use and somatic disease model (2: β = −0.13, P < 0.001), and also after adding lifestyle factors (model 3: β = −0.07, P < 0.001; Table 3). In those with depressive symptoms, the mean level of the sum of the five carotenoids was 239.8 (95% CI = 237.2–242.7) vs 249.4 (95% CI = 248.1–250.9; standardized sum) in those without depressive symptoms after adjustment for sociodemographics (model 1: Cohen’s d = −0.30, P < 0.001; Figure 2b) and 238.7 (95% CI = 236.0–241.3) vs 244.0 (95% CI = 242.5–245.7) after additional adjustment for health and lifestyle factors (model 3: Cohen’s d = −0.16, P < 0.001; Figure 2b). Change in estimate analyses revealed that smoking, diet and to a lesser extent BMI had the greatest effects on the association (See Supplementary Table 3). The number of previously measured CES-D ≥ 16 tended to be related only for those who scored ≥ 16 at all three measurements (model 3: β = −0.03, P = 0.062). The pattern of results was similar across the individual carotenoids (see Supplementary Table 2).

Cross-lagged longitudinal analyses. Cross-lagged analyses revealed all CES-D variables at year 10 predicted carotenoids at year 15 after adjustment for sociodemographics (CES-D ≥ 16 model 1: β = −0.07, P < 0.001) as well as after adjustment for health and lifestyle factors (CES-D ≥ 16 model 3: β = −0.05, P = 0.002). Carotenoids at year 15 were not associated with CES-D at year 20 (model 3: β = −0.01, P = 0.560; Table 4).

DISCUSSION

Higher F2-isoprostanes and lower carotenoid levels were cross-sectionally associated with increased depressive symptoms. For the F2-isoprostanes this association was largely explained by the lifestyle factors smoking, diet and BMI. For the carotenoids, this association is partially attenuated by these factors but remains present even after controlling for them. Longitudinal analyses show that depressive symptoms predict both the F2-isoprostane and carotenoids levels 5 years later; however, neither marker predicts future depressive symptoms. Overall, the effect sizes found in this study were small in size.48
A recent meta-analysis\(^{10}\) found increased F2-isoprostanes in persons with major depressive disorder and depressive symptoms. This is in contrast with the results of the present study and may be explained by the fact that several of the studies in this meta-analysis took into account some, but not all of the health and lifestyle factors included in these analyses. Previous large scale studies also reported decreased carotenoid levels in depressive symptoms.\(^{17,18}\) A novel finding in this study is that the association remains present even after controlling for diet quality, which should be considered an important confounder as dietary intake is involved in oxidative stress will be necessary to successfully understand the complex biological processes underlying the association between oxidative stress and anti-oxidants with depression.\(^{64}\) There is some evidence to suggest that antidepressants have antioxidant properties and may act through reducing pro-inflammatory cytokines and ROS production and improving levels of antioxidants such as superoxide dismutase.\(^{65}\) A number of studies have demonstrated that successful treatment with antidepressants decreases markers of oxidative stress and/or increases markers of antioxidant activity.\(^{57-61}\) However, these findings are limited and conflicting.\(^{19,62-66}\) To illustrate, Chung et al.\(^{64}\) found that serotonin re-uptake inhibitor treatment actually increased F2-isoprostane levels, despite reducing depressive symptoms.

Our results suggest that health and lifestyle factors are important mechanisms in the association between depressive symptoms and oxidative stress, especially for F2-isoprostanes. The lower carotenoid levels found in depressive symptoms may be a consequence of relatively low intake of foods rich in carotenoids, such as fruits and vegetables; a dietary pattern that has previously been associated with depression.\(^{49,50}\) In this study, however, the association between depressive symptoms and carotenoids was also present after adjusting analyses for a measure of diet quality. Other unhealthy lifestyle behaviors associated with depressive symptoms, such as smoking and alcohol consumption, increase the exposure to oxidative damage, as reflected by increased F2-isoprostane levels.\(^{51}\) One of the mechanisms by which smoking may decrease carotenoids levels is through causing an increase in metabolic rate, which in turn increases oxidative stress exposure, leading to a higher expenditure of antioxidant micronutrients such as the carotenoids.\(^{52}\) Exposure of human plasma to cigarette smoke has been shown to reduce carotenoids and other antioxidant levels.\(^{53}\)

There is also evidence suggesting that common genetic factors underlie both low carotenoid levels and depressive symptoms: a recent study demonstrated a single-nucleotide polymorphism associated with low levels of \(\beta\)-cryptoxanthin was also associated with depressive symptoms.\(^{35}\)

Besides increased exposure to ROS from exogenous sources owing to poor health and lifestyle behaviors, there is evidence to suggest that depression is also accompanied by increased endogenous production of ROS, possibly through mitochondrial dysfunction.\(^{55}\) The brain is particularly vulnerable to oxidative damage owing to its large oxygen consumption and relatively weak antioxidant defenses. Sustained oxidative brain damage during a depressive episode may make a sufferer prone to developing another depressive episode. Therefore, it has been hypothesized that exposure to oxidative stress could be an explanatory mechanism in the remitting and chronic course of depressive disorders.\(^{56}\)

| Table 3. Cross-sectional multivariable associations of F2-isoprostanes and carotenoids with depressive symptoms (CES-D)\(^a\) |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| CARDIA exam year 15            | Model 1         | Model 2         | Model 3         |
|                                | Age, sex, race, education | Age, sex, race, education, somatic disease, supplement use | Age, sex, race, education, somatic disease, supplement use, diet, BMI, smoking, alcohol, physical activity |
| F2-isoprostanes                |                 |                 |                 |
| CES-D score                    | 2968            | 2955            | 2926            |
| CES-D ≥ 16                     | 2968            | 2955            | 2926            |
| CES-D ≥ 16 and/or AD use       | 2968            | 2955            | 2926            |
| N CES-D ≥ 16\(^b\)             | 2592            | 2582            | 2558            |
| 1                              | 0.03            | 0.03            | 0.03            |
| 2                              | 0.05            | 0.05            | 0.03            |
| 3                              | 0.04            | 0.04            | 0.01            |
| Sum of five carotenoids\(^c\)  |                 |                 |                 |
| CES-D score                    | 2865            | 2853            | 2825            |
| CES-D ≥ 16                     | 2865            | 2853            | 2825            |
| CES-D ≥ 16 and/or AD use       | 2865            | 2853            | 2825            |
| N CES-D ≥ 16\(^b\)             | 2508            | 2499            | 2475            |
| 1                              | –0.13           | –0.13           | –0.07           |
| 2                              | –0.11           | –0.10           | –0.06           |
| 3                              | –0.07           | –0.07           | –0.07           |

Abbreviations: AD, antidepressant; BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults; CES-D, Center for Epidemiologic Studies Depression Scale; N, number; Ref, reference. \(^{a}\)F2-isoprostanes and carotenoids are log-transformed for linear regression analysis. Results are reported as standardized regression coefficients. All the results are adjusted for CENTER at baseline. \(^{b}\)Comparison of 1, 2 or 3 CES-D ≥ 16 with CES-D score 0 ≥ 16 over years 5, 10, 15 as reference group. \(^{c}\)Sum of standardized values (t-scores) of zeaxanthin/lutein, \(\beta\)-cryptoxanthin, lycopene, \(\alpha\)-carotene, \(\beta\)-carotene.
in diseases in which the role of oxidative stress is considered well established (such as cancer), the results of preventive treatment with antioxidants have been disappointing, or even harmful.68–70 The paradigm within which oxidative stress is perceived as damaging and antioxidants as protective is likely not an adequate model to this end. Although previously ROS were thought of purely as damaging to cells, the vital role they play in defense against pathogens and intracellular signaling is now recognized. Similarly antioxidants should not be thought of purely as benevolent factors. The finding that β-carotene supplementation in smokers lead to a significant increase in lung cancer incidence,71,72 is a clinical example of this. Omega-3 fatty acids are among the most widely studied supplements for the treatment of depression and may reduce oxidative stress through their anti-inflammatory properties. A recent meta-analysis of randomized trials found that they indeed reduce depressive symptoms in patients with a diagnosis of major depressive disorder or increased depressive symptoms.73 The effect of carotenoid supplements on depression has (to our knowledge) not yet been investigated, but observational data suggest that dietary patterns are associated with depressive symptoms.4 The same can be said of smoking, alcohol use, obesity and physical inactivity, all of which occur more frequently in those with depressive symptoms,4,13–15 and all of which are associated with oxidative stress.9,11 This suggests that addressing these behaviors may be the most effective course of action in depression.

This study has some important limitations. Although the CES-D is a well-established and sensitive tool for assessing depressive symptoms, like most self-report questionnaires for depression it lacks the specificity of diagnosis by a clinician or through a (semi-
Table 4. Cross-lagged longitudinal multivariable analyses of F2-isoprostanes and carotenoids with depressive symptoms (CES-D)*

| CARDIA exam years 10, 15 and 20 | Model 1 | Model 2 | Model 3 |
|--------------------------------|---------|---------|---------|
| **Independent variable** | **Dependent variable** | **Adjusted for** | **Age, sex, race, education** | **Age, sex, race, education, somatic disease, supplement use** | **Age, sex, race, education, somatic disease, supplement use, diet, BMI, smoking, alcohol, physical activity** |
| **F2-isoprostanes** | | | | | |
| CES-D\(^b\) | F2-isoprostanes 5 years later | Previous F2-isoprostane levels | 2334 | 0.06 | 0.001 | 2321 | 0.05 | 0.002 | 2304 | 0.03 | 0.064 |
| CES-D \(\geq\) 16\(^b\) | F2-isoprostanes 5 years later | Previous F2-isoprostane levels | 2334 | 0.05 | 0.003 | 2321 | 0.05 | 0.004 | 2304 | 0.03 | 0.048 |
| CES-D \(\geq\) 16 and/or AD\(^b\) | F2-isoprostanes 5 years later | Previous F2-isoprostane levels | 2334 | 0.06 | < 0.001 | 2321 | 0.06 | 0.001 | 2304 | 0.04 | 0.012 |
| F2-isoprostanes\(^c\) | CES-D 5 years later | Previous CES-D scores | 2589 | 0.04 | 0.028 | 2576 | 0.04 | 0.028 | 2506 | 0.03 | 0.095 |
| **Sum of five carotenoids\(^d\)** | | | | | |
| CES-D\(^e\) | Sum of five carotenoids 5 years later | Previous carotenoid levels | 2356 | −0.07 | < 0.001 | 2347 | −0.07 | < 0.001 | 2306 | −0.05 | 0.004 |
| CES-D \(\geq\) 16\(^e\) | Sum of five carotenoids 5 years later | Previous carotenoid levels | 2356 | −0.06 | < 0.001 | 2347 | −0.06 | < 0.001 | 2306 | −0.05 | 0.002 |
| CES-D \(\geq\) 16 and/or AD\(^e\) | Sum of five carotenoids 5 years later | Previous carotenoid levels | 2356 | −0.06 | < 0.001 | 2347 | −0.06 | < 0.001 | 2306 | −0.05 | 0.004 |
| Sum of five carotenoids\(^f\) | CES-D 5 years later | Previous CES-D scores | 2504 | −0.03 | 0.069 | 2492 | −0.03 | 0.086 | 2476 | −0.01 | 0.560 |

Abbreviations: AD, antidepressant; BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults; CES-D, Center for Epidemiologic Studies Depression Scale; N, number. *F2-isoprostanes and carotenoids log-transformed for linear regression analysis. Results are reported as standardized regression coefficients. All the results are adjusted for CENTER at baseline. \(^b\)CES-D at year 15, F2-isoprostanes at year 20, covariates at year 15; adjusted for F2-isoprostanes at year 15. \(^c\)F2-isoprostanes at year 15, CES-D at year 20, covariates at year 15; adjusted for CES-D scores at year 15. \(^d\)Sum of standardized (t-scores) zeaxanthin/lutein, \(\beta\)-cryptoxanthin, lycopene, \(\alpha\)-carotene, \(\beta\)-carotene. \(^e\)CES-D at year 10, sum of five carotenoids at year 15, covariates at year 10; adjusted for carotenoids at year 7 (as there are no data on carotenoids available in year 10 (see Figure 1)). \(^f\)Sum of five carotenoids at year 15, CES-D at year 20, covariates at year 15; adjusted for CES-D scores at year 15.
structured interview. This may have led to misclassification of some subjects in this study as being depressed. In addition, due to the observational design and the varying availability of oxidative stress, antioxidant and depression data at different time points, the possibilities for examination of the longitudinal associations were limited. The effect sizes are statistically significant but small; this should be considered when interpreting the potential clinical impact of the association. Individual markers of oxidative stress and/or antioxidants cannot and do not fully reflect the ongoing and complex biological process of redox homeostasis. This limitation applies to all human studies in the field of oxidative stress and should be considered in the interpretation of all study results. F2-isoprostanes reflect oxidative lipid damage, but are only one product of lipid peroxidation. Furthermore oxidative damage also affects DNA and proteins, but markers of these processes such as 8-OHdG and protein carbonyls, are not available in this study. Although carotenoids are important potent antioxidants, their levels do not reflect all aspects of the antioxidant defense system, that includes many more enzymatic (for example, superoxide dismutase, catalase) and non-enzymatic antioxidants (ascorbic acid). The main strengths of this study are the large sample size, the measurements of circulating F2-isoprostanes and carotenoids with gold-standard techniques, the ability to control for a wide range of important health and lifestyle confounders, and determination of the temporal associations between depression and F2-isoprostanes and carotenoids.

In conclusion, this study demonstrates that F2-isoprostanes and carotenoids are associated with depressive symptoms, both cross-sectionally and longitudinally, and that health and lifestyle factors are important mechanisms in this association, especially in F2-isoprostanes. Further large scale research on oxidative stress and antioxidants should investigate these associations in individuals meeting the diagnostic criteria for a mood disorder.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C) and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between NIA and NHLBI (AG0005). This manuscript has been reviewed by CARDIA for scientific content. The Young Adult Longitudinal Trends in Antioxidants Study (YALTA) is supported by the National Heart, Lung, and Blood Institute, National Institutes of Health (RO1 HL 53560). CNB and BWJHP are supported through an NWO-VICI grant (number 91811602).

REFERENCES
1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–2196.
2. Penninx BWJH, Milaneschi Y, Lameser F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11: 129.
3. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 146 538 participants in 54 observational studies. Eur Heart J 2006; 27: 2763–2774.
4. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuypers P, Penninx BWJH, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220–229.
31 Eilasson AH, Liao X, Rosner B, Tamimi RM, Tworoger SS, Hankinson SE. Plasma carotenoids and risk of breast cancer over 20 y of follow-up. Am J Clin Nutr 2015; 101: 1197–1205.

32 Jamova K, Valko M. Health protective effects of carotenoids and their interactions with other biological antioxidants. Eur J Med Chem 2013; 70: 102–110.

33 Fiedor J, Burda K. Potential role of carotenoids as antioxidants in human health and disease. Nutrients 2014; 6: 466–488.

34 Meyer KA, Sijtsma FPC. Nettleton JA, Steffen LM, Horn L, Van, Shikany JM et al. Dietary patterns are associated with plasma F2-isoprostanes in an observational cohort study of adults. Free Radic Biol Med 2014; 57: 1–20.

35 Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutical implications. Mol Psychiatry 2013; 18: 595–606.

36 Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41: 1105–1116.

37 Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977: 1: 385–401.

38 Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 2006; 62: 123–146.

39 Morrow JD, Roberts LJ 2nd. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidative stress. Methods Enzymol 1999; 300: 3–12.

40 Gross M, Steffes M, Jacobs DR, Yu X, Lewis L, Lewis CE et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA study. Clin Chem 2005; 51: 125–131.

41 Bieri JG, Brown ED, Smith JC. Determination of individual carotenoids in human-plasma by high-performance liquid-chromatography. J Liq Chromatogr 1985; 8: 473–484.

42 Craft NE, Brown ED, Smith JC. Effects of storage and handling conditions on concentrations of individual carotenoids, retinol, and tocopherol in plasma. Clin Chem 1988; 34: 44–48.

43 Gross MD, Prouty CB, Jacobs DRJ. Stability of carotenoids and alpha-tocopherol during blood collection and processing procedures. Clin Chem 1995; 41: S934–S944.

44 Iribarren C, Folsom AR, Jacobs DRJ, Gross MD, Prouty CB, Jacobs DRJ. Association of oxidative stress and anti-oxidants with depression in patients with major depressive treatment. Arch Med Res 2007; 38: 247–252.

45 Cumurcu BE, Ozyurt H, Etkan I, Demir S, Karlildag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 2009; 63: 639–645.

46 Fiedor J, Burda K. Potential role of carotenoids as antioxidants in human health and disease. Nutrients 2014; 6: 466–488.

47 Gawryluk JW, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1284–1290.

48 Cohen J.

49 McMartin SE, Jacka FN, Colman I. The association between fruit and vegetable consumption and mental health disorders: evidence from a national survey of Canadians. Environ Sci Pollut Res Int 2013; 20: 1517–1527.

50 Payne ME, Steck SE, George RR, Steffens DC. Fruit, vegetable, and antioxidant intakes are lower in older adults with depression. J Acad Nutr Diet 2012; 112: 2022–2027.

51 Aseervatham GSB, Sivasudha T, Jeyadevi R, Ananth D. Environmental factors and unhealthy lifestyle influence oxidative stress in humans—an overview. Environ Sci Pollut Res Int 2013; 20: 4356–4359.

52 Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology 2002; 180: 121–137.

53 Handelman GJ, Packer L, Cross CE. Destruction of tocopherols, carotenoids, and retinol in human plasma by cigarette smoke. Am J Clin Nutr 1996; 63: 559–565.

54 Beydoun MA, Nalls MA, Canas JA, Evans MK, Zonderman AB. Gene polymorphisms and gene scores linked to low serum carotenoid status and their associations with metabolic disturbance and depressive symptoms in African-American adults. Br J Nutr 2014; 112: 992–1003.

55 Hrudová J, Fišar Z. Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin Neurosci 2011; 65: 130–141.

56 Lee S-Y, Lee S-J, Han C, Patkar AA, Masand PS, Pae C-U. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 224–235.

57 Khanzode SD, Dakhale GN, Khanzode SS, Saogi A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin reuptake inhibitors. Redox Rep 2003; 8: 365–370.

58 Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009; 24: 277–286.

59 Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007; 38: 247–252.

60 Cumurcu BE, Ozyurt H, Etkan I, Demir S, Karlildag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 2009; 63: 639–645.